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Abstract
Scientific revolution [1] implies a transformation of the world view in which a dominant paradigm is substituted by a new
one, one which furnishes an ameliorated comprehension of facts, as well as an advantage for the design of informative
experiments. Apoptosis research has recently experienced a change from a paradigm in which the nucleus determined the
apoptotic process to a paradigm in which mitochondria constitute the center of death control. Several pieces of evidence
imply mitochondria in the process of apoptosis. Kinetic data indicate that mitochondria undergo major changes in
membrane integrity before classical signs of apoptosis become manifest. These changes concern both the inner and the outer
mitochondrial membranes, leading to a disruption of the inner transmembrane potential (v8m) and the release of
intermembrane proteins through the outer membrane. Cell-free systems of apoptosis demonstrate that mitochondrial
products are rate limiting for the activation of caspases and endonucleases in cell extracts. Functional studies indicate that
drug-enforced opening or closing of the mitochondrial megachannel (also called permeability transition pore) can induce or
prevent apoptosis. The anti-apoptotic oncoprotein Bcl-2 acts on mitochondria to stabilize membrane integrity and to prevent
opening of the megachannel. These observations are compatible with a three-step model of apoptosis: a premitochondrial
phase during which signal transduction cascades or damage pathways are activated; a mitochondrial phase, during which
mitochondrial membrane function is lost ; and a post-mitochondrial phase, during which proteins released from
mitochondria cause the activation of catabolic proteases and nucleases. The implication of mitochondria in apoptosis has
important consequences for the understanding of the normal physiology of apoptosis, its deregulation in cancer and
degenerative diseases, and the development of novel cytotoxic and cytoprotective drugs. ß 1998 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Apoptosis can be de¢ned as a cell death process in
which activation of catabolic processes and enzymes
occurs prior to cytolysis, thereby facilitating the rec-
ognition, uptake, and digestion of the apoptotic cell
by dying neighboring cells. During several decades, it
has been assumed that the activation of endonu-
cleases and speci¢c proteases involved in apoptosis
(the caspases) would re£ect the key mechanism of
apoptosis. Moreover, it has been long thought that
mitochondria would not be involved in apoptosis.
This assumption was based on the observations
that during apoptosis, mitochondria do not undergo
spectacular morphological changes, and that cells
whose mitochondria lack mitochondrial DNA (b‡
cells) maintain the capacity to undergo apoptosis.
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Table 1
Cell death inducers causing a v8m disruption which precedes signs of apoptosis or cytolysis
Group of agents Examples (active principle) Inducer reported to cause
apoptosis (A)/necrosis (N)a
References
Hormones and cytokines Glucocorticoids (steroid hormone) A/Nb [8,9,11,41,96]
Tumor necrosis factor (in£ammatory cytokine) A/N [9,12,24,97,98]
Crosslinking of pro-
apoptotic receptors
CD3O (part of the T-cell receptor complex) A [9,11]
Fas/Apo-1/CD95 (death-inducing receptor) A [11,17,99,100]
IgM (part of the B-cell receptor complex) A [16]
CD45 (on thymocytes) A? [101]
CD99 (on thymocytes) A? [102]
Depletion of growth factors Nerve cell growth factor A [103,104]
Serum withdrawal A [11,104]
Pro-apoptotic intracellular
signals
Ca2 increase A/N [23,78,105,106]
Ceramide A/Nb [9,11,17,74,75]
Ganglioside GD3 (ceramide derivative) A [75]
Nitric oxide A/N [107]
Staurosporin (inhibitor of tyrosine kinases) A [43,108]
Herbimycin A (inducer of terminal di¡erentiation) A [109]
Overexpression of Bax (Bcl-2 antagonist) A/Nb [26]
Activation of p53 (anti-oncogene) A [15]
Amphipathic peptides Mastoparan N [43]
Pro-oxidants H2O2 A/N [16,110]
ter-butylhydroperoxide A/N [11,16,90,111,112]
Menadione (redox-cycling agent) A/N [9,40]
Tetramethylrhodamine ethyl ester (intramito-
chondrial generation of reactive oxygen species)
N [113]
Diamide (thiol crosslinking agent) A [10,20,56]
Inhibitors of oxidative
phosphorylation
Rotenone (complex I inhibitor) A/N [15,64]
Antimycin A (complex II inhibitor) A/N [12,64]
Cyanide (complex IV inhibitor) A/N [114,115]
Oligomycin (complex V inhibitor) A/N [11]
mClCCP (protonophore) A/N [10]
Physical damage Ionizing irradiation A [40,116]
Ischemia-reperfusion damage A/N [117,118]
Viral infection Human immunode¢ciency virus (HIV-1) A [39,119^121]
Papillomavirus 16 E6 A [122]
Classical swine fever virus A [123]
Chemotherapeutic agents Etoposide (topoisomerase II inhibitor) A/Nb [11,16,64]
Camptothecin (topoisomerase I inhibitor) A [124]
Doxorubicin (antimetabolite) A [16]
Cytosine arabinoside (antimetabolite) A [16,28,125]
(continued on next page)
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However, it has now become clear that mitochondria
do exhibit major changes in their structure and func-
tion during apoptosis (for review see [2^7]). Mito-
chondria are now considered major players in the
apoptotic process of mammalian cells, as demon-
strated by our group [8^20] and by others [21^26]
[27^33]. This review on the involvement of mitochon-
dria in apoptosis will concentrate on recent contro-
versies raised in this rapidly moving ¢eld.
2. Mitochondria in apoptosis: doubt no more
Four major arguments suggest the involvement of
mitochondria in apoptosis. First, kinetic studies in-
dicate that mitochondria undergo major changes in
membrane integrity before classical signs of apopto-
sis become manifest. Second, cell-free systems dem-
onstrate that mitochondrial products are rate limit-
ing for the activation of caspases and endonucleases
in cell extracts. Third, pharmacological data indicate
that certain drugs which stabilize mitochondrial
membranes can prevent apoptosis. Fourth, extensive
analysis of the proto-oncogene product Bcl-2 and of
its homologs has revealed that they act on mitochon-
dria to regulate apoptosis. Here, we will brie£y sum-
marize the evidence implying mitochondria in apop-
tosis.
2.1. Kinetic data implying mitochondria in apoptosis
Lipophilic cations accumulate in the mitochondrial
matrix, driven by the electrochemical gradient fol-
lowing the Nernst equation, according to which
every 61.5 mV increase in membrane potential (usu-
ally 120^170 mV) corresponds to a ten-fold increase
in cation concentration in mitochondria. Therefore,
the concentration of such cations is two to three logs
higher in the mitochondrial matrix than in the cyto-
sol. Cationic lipophilic £uorochromes such as 3,3P-
Table 1 (continued)
Group of agents Examples (active principle) Inducer reported to cause
apoptosis (A)/necrosis (N)a
References
Trichostatin A (inhibitor of histone acetylase) A [126]
Tamoxifen (estrogen receptor antagonist) A [43]
2-Chloroadenosine (antimetabolite) A [127]
Geranylgeranoic acid A [128]
Betulinic acid A [129]
Neurotoxins Glutamate (excitotoxin) A/N [23,87,130]
N-methyl-D-aspartate A/N [131]
1-Methyl-4-phenylpyridinium N [132,133]
Dopamine A/N [134]
Amyloid-M-peptide A/N [135,136]
Presenilin-1 A [137]
Lysophosphatidic acid A/N [138]
Hepatotoxins Protoporphyrin IX (PBR ligand) A/Nb [15,139]
Ethanol A/N [140,141]
Salicylate (causes Reye’s syndrome) N [142]
Glycochenodeoxycholate N [143]
1,3-Dichloropropanol N [144]
Lipopolysaccharide (bacterial toxin) A/N [145]
Nephrotoxins Atractyloside (ligand of the ANT) A [122]
1,2-Dichlorovinyl-L-cysteine (oxidative stress) N [146]
Non-steroidal anti-in£ammatory agents, such as
diclofenac sodium or efenamic acid
N [147]
aNote that in several cases, no major e¡orts have been undertaken to distinguish the mode of cell death.
bExamples in which addition of the caspase inhibitor Z-VAD.fmk prevent acquisition of the apoptotic phenotype and instead causes
cytolysis without apoptosis.
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dihexyloxacarbocyanine iodide (DiOC6(3)), 5,5P,6,6P-
tetrachloro-1,1P,3,3P-tetraethylbenzimidazolcarbocya-
nine iodide (JC-1), and chloromethyl-X-rosamine
(CMXRos) can be employed for the cyto£uorometric
determination of the mitochondrial inner transmem-
brane potential (v8m) [34,35]. In most cases of apop-
tosis, a disruption of the v8m resulting in a diminu-
tion of dye uptake precedes all major changes in cell
morphology and biochemistry including nuclear
DNA fragmentation and phosphatidylserine expo-
sure in the outer lea£et of the plasma membrane
(Table 1). In addition to the disruption of the
v8m, mitochondria exhibit a number of profound
changes in structure and function during apoptosis.
Thus, cytochrome c, a protein normally con¢ned to
the mitochondrial intermembrane space, is found in
the cytosol of cells undergoing apoptosis according
to some [25,28^30,36], but not all [37], reports. This
change is indicative of an enhanced permeability of
the outer membrane and occurs relatively early, to-
gether with or before the disruption of the v8m,
before DNA fragmentation occurs [28^30]. A func-
tional inactivation of cytochrome c function without
release into the cytosol has also been reported by one
group [37,38]. During apoptosis, mitochondria tend
to produce enhanced levels of superoxide anion and
oxidize the inner membrane lipid cardiolipin [9,39].
These latter changes mostly occur after disruption of
the v8m [9,11,18,39^41]. In conclusion, the perme-
ability and function of the inner and/or outer mito-
chondrial membranes is a¡ected early during the
apoptotic process.
2.2. Cell-free systems suggesting the implication of
mitochondria in apoptosis
Cell-free systems are designed to recapitulate es-
sential steps of the apoptotic process in vitro by mix-
ing together cell extracts and puri¢ed organelles.
Careful puri¢cation of organelles and cytosols re-
vealed that induction of nuclear apoptosis (chroma-
tin condensation and DNA fragmentation) required
the addition of mitochondria or mitochondrial prod-
ucts [10,14,21,42]. Although mitochondria from
healthy cells are inert in such an experimental sys-
tem, they do release apoptogenic factors upon addi-
tion of cytosolic extracts from dying cells [17,21,42].
This requirement can be overcome by addition of
inducers of the so-called permeability transition (see
below) [10,12,43]. Irrespective of controversies re-
garding details on the molecular mechanisms of
apoptosis, the data obtained in cell-free systems are
compatible with a two-step model. In the ¢rst step,
di¡erent inducers formed in the cytosol (such as
Ca2, pro-oxidants, caspases, and perhaps protein
kinases) act on mitochondria to induce PT, thereby
causing v8m disruption and release of apoptogenic
proteins. Such proteins, the so-called apoptosis-in-
ducing factors (AIF) or apoptotis protease-activating
factors (Apaf), then cause caspase activation as well
as apoptotic changes in normal puri¢ed nuclei.
2.3. Functional data suggesting involvement of the
mitochondrial megachannel in apoptosis
When studying the loss of mitochondrial function
occurring during apoptosis, we considered two pos-
sibilities. The disruption of the v8m could be attrib-
uted to non-speci¢c damage of the inner mitochon-
drial membrane or, alternatively, to a more speci¢c
process. The so-called permeability transition (PT) is
due to the opening of a regulated proteaceous pore,
the mitochondrial megachannel, also called PT pore
[44^46]. The PT pore is a dynamic multiprotein com-
plex probably located at the contact site between the
inner and the outer mitochondrial membranes [47^
49]. Although the exact composition of the PT pore
complex is elusive, it is thought to involve proteins
from the cytosol (hexokinase), the outer membrane
(voltage-dependent anion channel, VDAC), the inner
membrane (the adenine nucleotide translocator,
ANT), and the matrix (cyclophilin D) [19,44,46^53].
The PT pore participates in the regulation of matrix
Ca2, pH, v8m, and volume, functioning as a Ca2-,
voltage-, pH-, and redox-gated channels with several
levels of conductance and little, if any, ion selectivity.
At its high level of conductance, it can provoke irre-
versible v8m dissipation [44,46,50,54].
To discriminate the above-mentioned possibilities
(membrane damage versus opening of the megachan-
nel), we incubated cells undergoing apoptosis with
inhibitors of the megachannel. We observed that a
ligand of the ANT, bongkrekic acid, and ligands of
cyclophilin D such as cyclosporin A and N-methyl-4-
Val-cyclosporin A that inhibit PT, also prevent the
loss of the v8m in several models of apoptosis [9,55].
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Since cyclosporin A, for unknown reasons, is a tran-
sient inhibitor of PT [44], its v8m-stabilizing e¡ect is
only revealed in experiments designed to last 60 min
or less [9,11,41,55]. In contrast, BA has a long-term
protective e¡ect on mitochondrial function as de-
scribed by us [10,11,13,15] and con¢rmed by others
[31]. This establishes the implication of the mega-
channel in apoptotic v8m disruption. In addition,
inhibitors of the megachannel, such as bongkrekic
acid and chloromethyl-X-rosamine (a thiol-reactive
agent distributing into the mitochondrial matrix) pre-
vent the mitochondrial and post-mitochondrial signs
of apoptosis [10,13,15,31,56]. Conversely, induction
of permeability transition causes disruption of the
v8m, followed by full-blown apoptosis [13,15,18,
24]. Thus, opening of the megachannel appears
both su⁄cient and necessary for the induction of
apoptosis, at least in those models that we have
studied.
2.4. Bcl-2 acts on mitochondrial targets to inhibit
apoptosis
Bcl-2 belongs to a growing family of proteins
which can either inhibit (Bcl-2, Bcl-XL, Bcl-2w,
Mcl-1, B£-1, A1 etc.) or favor (Bax, Bcl-XS, Bad,
Bak, Bik etc.) apoptosis [5,57]. Enhanced expression
of Bcl-2 or of its apoptosis-inhibitory homologs is
involved in the pathogenesis of numerous human
cancers. The hydrophobic C terminus of Bcl-2 incor-
porates into the outer mitochondrial membrane,
whereas the N-terminus faces the cytosol. It exhibits
a non-homogeneous, scattered distribution in the
proximity of the inner/outer membrane contact site
[58]. The preferential enrichment of Bcl-2 proteins in
the contact site explains past di⁄culties in assigning
its localization to the inner versus outer mitochon-
drial membrane [59]. At least in some experimental
models, Bcl-2 exerts its apoptosis-inhibitory e¡ect
only if it is present in the mitochondrion rather
than in other subcellular sites [60^63]. Bcl-2 prevents
signs of PT in cells [8,9,16,64], cytoplasts (= cells lack-
ing nuclei) [11,16], as well as in isolated mitochondria
[10,14,15,56]. Moreover, it prevents the mitochon-
drial release of apoptogenic proteins [10,14,28,29],
the uncoupling of the respiratory chain occurring
during apoptosis [9], the oxidation of the inner mem-
brane constituent cardiolipin [9], and the release of
small molecules, such as calcium, from the mitochon-
drial matrix [65]. These data suggest that Bcl-2, and
probably other members of the Bcl-2 family, regulate
apoptosis, at least in part, due to their capacity to act
on mitochondria, perhaps as an endogenous inhibi-
tor of the pore-forming protein Bax [66] or via in-
dependent mechanisms [67]. The exact molecular
mechanisms via which Bcl-2 prevents PT remain elu-
Fig. 1. Phases of the apoptotic process. During the pre-mito-
chondrial induction phase, di¡erent pro-apoptotic signal trans-
duction pathways are activated. These pathways are ‘private’ in
the sense that the molecular events involved in them depend on
the initial apoptosis trigger. Thus, genotoxic stress involves p53
transcription and generation of reactive oxygen species, which
are not involved in Fas-induced apoptosis, to give just one ex-
ample. The common mitochondrial phase is characterized by
changes in mitochondrial membrane function with increases in
the inner and/or outer membrane permeability. Ampli¢ers of
these mitochondrial changes engage in a self-amplifying feed-
back loop. Such ampli¢ers include the activation of caspases
and local changes in voltage and redox potentials. It may be,
during this mitochondrial phase, that the ‘decision to die’ is
made. The post-mitochondrial degradation phase, beyond the
point-of-no-return, is characterized by the action of caspase and
nuclease activators released from mitochondria, as well as by
the bioenergetic and redox changes caused by a collapse of mi-
tochondrial function.
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sive. However, it appears that this e¡ect is a direct
one, because the opening of PT pore complexes re-
constituted into liposomes is inhibited by Bcl-2 and
Bcl-XL [7,19,20].
Altogether, these data are compatible with a (near
to) general mechanism of apoptosis in which three
phases can be distinguished: (1) a pre-mitochondrial
phase (induction phase) during which, depending on
the apoptosis-inducing stimulus, a large variety of
signal transduction cascades or damage pathways
can be activated; (2) a mitochondrial phase (e¡ector
phase) during which mitochondrial membrane integ-
rity is lost and the ‘decision to die’ is made; and (3) a
post-mitochondrial phase (degradation phase) during
which soluble factors released by mitochondria acti-
vate catabolic hydrolases responsible for the apop-
totic degradation of essential proteins and nuclear
DNA (Fig. 1).
3. The pre-mitochondrial phase of apoptosis: how
mitochondria integrate di¡erent pro-apoptotic
pathways
The PT pore complex has been proposed to be
located with the inner/outer membrane contact sites,
a site of metabolic coordination between the mito-
chondrial matrix, the intermembrane space, and the
cytosol [19,47^49]. In accordance with its localization
and with its composite structure, the PT pore com-
plex can be viewed as an integrator which senses
metabolic perturbations [2,4,6,44,46,50,68]. In addi-
tion, it appears that several pro-apoptotic signal
transduction pathways can induce PT (Fig. 2).
3.1. Redox metabolism
Major perturbations of intermediate metabolism
may provoke PT via a number of di¡erent mecha-
nisms. Thus, changes in cellular redox potentials due
to an enhanced generation of reactive oxygen species
(or a decrease in their detoxi¢cation), depletion of
non-oxidized glutathione, or depletion of NAD(P)H2
su⁄ce to induce or facilitate PT [44,46,50]. The mi-
tochondrial megachannel possesses several redox-
sensitive sites, one that is at equilibrium with mito-
chondrial matrix glutathione, and one that can be
directly activated by reactive oxygen species [69].
An enhanced generation of reactive oxygen species
is not always the result of cellular damage; it also
Fig. 2. Inducers of permeability transition. Di¡erent signal transduction pathways can promote the activation of caspases, increases in
cytosolic Ca2 level, nitric oxide, amphipathic peptides, and ceramide, which can provoke PT either in a direct or an indirect fashion.
In addition, changes in the composition of the Bcl-2 complex, such as hyperexpression of the Bcl-2 antagonists Bax or Bak, may in-
duce PT. Major changes in the cellular redox balance or in bioenergetic parameters can also trigger PT. Note that PT is a self-ampli-
fying process in the sense that several consequences of PT themselves can provoke PT (two-headed arrows). For Ca2-induced PT
consult, e.g. [44,148^150], for AIF [17], for caspases [17,19], for Bcl-2-mediated regulation of PT [10,14], for NO [107,153], for amphi-
pathic peptides [43,154], for decrease of the v8m [155,158,159], for ceramide [17], for redox alterations [50,69,151,152], and for ATP
depletion [166]. Note that ceramide does not cause PT in a direct fashion, but rather acts via other second messengers [17].
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can result from overexpression of the pro-apoptotic
anti-oncogene p53 [31] or from treatment of cells
with the second messenger ceramide [70].
3.2. Energy metabolism
ADP and ATP are the physiological ligands of the
adenine nucleotide translocator and function as en-
dogenous inhibitors of PT [44,46,50,71]. Their deple-
tion therefore facilitates PT. In addition, a reduction
of the v8m and matrix alkalinization can also trigger
PT [44,46,50]. Thus, uncoupling or inhibition of the
respiratory chain (which leads to a decrease in v8m)
or inhibition of F1ATPase (which causes matrix al-
kalinization) may favor PT.
3.3. Ceramide
Ceramide is produced in response to several apop-
tosis-inducing stimuli, including signalling via the
Fas/Apo-1 surface receptor or the tumor necrosis
factor receptor, non-speci¢c stress, or cytotoxic drugs
[72,73]. According to several authors, ceramide indu-
ces PT when added to cells [9,11,17,74,75], but does
not induce PT in isolated mitochondria [17,74,76].
According to one group, ceramide can induce PT
in isolated mitochondria [77]. Ceramide has also
been reported to enhance the generation of reactive
oxygen species by mitochondria, thereby depleting
the pool of matrix glutathione [76]. We have found
that cytosols from ceramide-treated cells are e⁄cient
inducers of PT in isolated mitochondria from un-
treated control cells. However, the addition of ce-
ramide to cytosols does not generate a PT-inducing
activity [17,74]. This suggests that, in intact cells,
ceramide triggers the generation of a secondary mes-
senger or metabolite which then accounts for the
induction of PT. In accordance with this hypothesis
[17,74], it has been demonstrated that ceramide
causes apoptosis via eliciting the generation of gan-
glioside 3 in the Golgi apparatus [75]. Ganglioside 3
can disrupt the v8m when added to cells [75]. How-
ever, it still remains unknown whether ganglioside 3
can act directly on mitochondria.
3.4. Cytosolic calcium
Ca2 ions are among the most e⁄cient inducers of
PT. At supraphysiological doses (E10 WM), Ca2 is
su⁄cient to induce PT; at lower doses, it facilitates
the induction of PT by other stimuli [44,46,50]. In-
creases in free Ca2 concentrations are also impor-
tant co-mediators of apoptotic cell death. Indeed, the
induction of apoptosis by Ca2 can be prevented by
the PT pore inhibitor, cyclosporin A [78]. Moreover,
it appears that Bcl-2 overexpression enhances the
tolerance of mitochondria to Ca2 [79].
3.5. Bcl-2 and its homologs
The relative expression level of pro-apoptotic and
anti-apoptotic members of the Bcl-2 family is likely
to a¡ect mitochondrial membrane function. Indeed,
overexpression of Bax causes disruption of the v8m
[26], whereas Bcl-2 overexpression prevents mito-
chondrial changes associated with apoptosis (see
above). One plausible scenario predicts that the
pro-apoptotic Bcl-2 homolog Bax can form channels,
thereby disrupting the membrane barrier function,
and that Bcl-2 prevents channel formation by Bax
[66]. Thus, the transcription/translation levels of
Bcl-2 and its homologs would determine the fate of
cells. In addition, a number of post-translational
modi¢cations can a¡ect Bcl-2. Inactivation of Bcl-2
is achieved by chemotherapeutic agents acting on
microtubuli (such as taxol) which cause its hyper-
phosphorylation [80] and, simultaneously, favor
opening of the PT pore [81]. In addition, Bcl-2 can
be inactivated by proteases [82], and the subcellular
distribution of several Bcl-2-associated proteins is al-
tered by signal transduction pathways (reviewed in
[5]). This suggests that Bcl-2 and its homologs may
constitute a point of integration of several pro-apop-
totic pathways.
3.6. Caspases
Ligation of some receptors can lead to a near-to-
immediate activation of ‘caspases’, a family of pro-
teases (cysteine proteases cleaving after Asp residues)
which are activated via speci¢c proteolytic cleavage.
This has been ¢rst documented for the Fas/Apo-1/
CD95 receptor, which recruits caspase-8 into the re-
ceptor complex and causes its activation upon inter-
action with the Fas/Apo-1/CD95 ligand. We have
recently shown that caspases can act on yet unknown
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substrates in the mitochondrial membrane, thereby
inducing PT and the release of apoptogenic proteins
[17,19]. It appears plausible that primary caspase ac-
tivation is not su⁄cient to trigger the apoptotic cas-
cade and that the caspase-triggered release of mito-
chondrial apoptogenic factors is required in order to
drive the apoptotic process [17,27].
4. The mitochondrial phase of apoptosis: two
mitochondrial membranes ^ two mechanisms of
compromising membrane integrity?
As discussed above, the barrier function of the
inner and/or outer mitochondrial membrane is com-
promised early during apoptosis. At present, it is not
clear which among these membranes is a¡ected ¢rst
and whether the order in which these membranes are
a¡ected is always the same. Cyto£uorometric analy-
ses can be employed to show that the v8m collapses
(Table 2), indicating that the electrochemical gra-
dient of the inner membrane breaks down. However,
£ow cytometry will only identify those cells as v8lowm
in which the vast majority of mitochondria (s 70%)
have disrupted their v8m. Cells in which only part of
the mitochondria have lost their v8m will be de-
tected as v8highm . Moreover, it appears that the
v8m disruption is a two-step process, at least in eto-
poside- or glucocorticoid-triggered thymocyte cell
death [18]. In this model, in which we quantify the
v8m either with CMX-Ros or with DiOC6(3), the
transition from the v8highm to the v8
intermediate
m stage
does not require protease activation, whereas the
transition form the v8intermediatem to the v8
low
m stage
is retarded by the protease inhibitor Z-VAD.fmk.
Thus, the v8intermediatem population, which in most
experiments is rather small, is greatly expanded in
the presence of Z-VAD.fmk or other caspase inhib-
itors [18,83,84]. This illustrates the di⁄culty to sepa-
rate cells with a normal v8m from those with a low
v8m. To augment confusion in this area, in several
studies, rhodamine-123 has been used to quantify the
v8m in intact cells, although rhodamine-123 £uores-
cence does not always correlate with the v8m [85].
Table 2
Inducers and inhibitors of apoptosis acting on permeability transition pores
Inducers of permeability transition Inhibitors of permeability transition
Substance Putative target Substance Putative target
Endogenous
Ca2 Unknown [148^150] ADP, ATP ANT [71]
Oxidizing agents Matrix thiols? [69,151,152] Glucose Hexokinase [161]
Calcium chelators Calcium [148^150]
Nitric oxide Unknown [107,153] Mg2, Zn2 Unknown [148,149,162]
Caspases Unknown substrates in outer
mitochondrial membrane [17,19]
Protons Reversible histidyl
protonation [52,163]
Amphipathic peptides Membrane e¡ects? [43,154] Bcl-2, Bcl-XL Unknown [10,19]
Fatty acids ANT? [155^157]
Exogenous
Protoporphyrin IX PBR [24,139] Cyclosporin A (CsA),
N-methyl-4-Val-CsA
Cyclophilin D [52,164]
PK11195 PBR [24,139] Bongkrekic acid ANT [71]
Atractyloside ANT [71] Monochlorobiman,
Monobromobiman
Matrix thiols? [56,69,165]
Protonophores Inner mitochondrial membrane
[155,158,159]
Chloromethyl-X-rosamin Matrix thiols [56]
Disul¢de bridge forming
agents
Matrix thiols? [56,69,160] Calpain inhibitors Mitochondrial calpain-like
protease? [77]
Phosphotyrosine Tyrosine kinases? [10]
ANT, adenine nucleotide translocator; PBR, peripheral benzodiazepine receptor. Note that, for technical reasons, only a few referen-
ces could be cited.
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The notion that the outer mitochondrial mem-
brane is a¡ected during apoptosis is based on the
observation that after subcellular fractionation, cyto-
chrome c, which normally is con¢ned to mitochon-
dria, can be found in the cytosol [25,28,30,36]. How-
ever, this does not prove that cytochrome c is
actually in the cytosol of the living cells and could
mean that mitochondria are just more vulnerable to
the disruption of the outer membrane during the
fractionation process. It has been suggested that cy-
tochrome c may be released into the cytosol before
the v8m is lost, because cytosols derived from staur-
osporine- or etoposide-treated HL60 cells with a
largely intact v8m can contain cytochrome c [33].
Similar results have been reported for Jurkat cells
treated by CD95 crosslinking [32]. Recently, two
studies have employed in situ immuno£uorescence
techniques to show an early release of cytochrome
c in situ [33,86]. These observations have been inter-
preted to mean that cytochrome c release occurs in-
dependently of PT [28,30,32,33]. However, PT is a
reversible process [54], and cells that have undergone
PT (and have released cytochrome c?) can recover
their v8m before they undergo apoptosis [22,87].
Theoretically, two pathways could link the loss of
the barrier function on the two mitochondrial mem-
branes (Fig. 3). On the one hand, it is conceivable
that Bcl-2 is a primary regulator of PT and that PT,
which primarily a¡ects the inner membrane, then
causes cytochrome c release (Fig. 3A). Bcl-2 aug-
ments the resistance of mitochondria to atractylo-
side, a ligand of the inner transmembrane adenine
nucleotide translocator, that normally a¡ects the
v8m within seconds [10,14]. Moreover, it directly
inhibits the opening of the PT pore reconstituted
into liposomal membranes in an experimental system
in which no cytochrome c is present [7,19,20]. Induc-
tion of PT can trigger the release of cytochrome c
from isolated mitochondria in vitro [43,88]. On the
other hand (Fig. 3B), Bcl-2 could primarily a¡ect the
integrity of the outer membrane, as suggested by the
fact that it is located in the outer membrane (but in
the contact site with the inner membrane!). Bcl-2
could interact with cytochrome c, either in a direct
fashion, as this has been suggested for Bcl-XL [36], or
in an indirect fashion, via Apaf-1, which binds to
both Bcl-2 and cytochrome c [89]. Once cytochrome
c is released through the outer membrane, the result-
ing dysfunction of the respiratory chain might favor
PT. At present, it is not clear whether these two
scenarios are incompatible and, if so, which among
them will prevail. It remains to be determined
whether the PT pore complex could regulate the per-
meability of both the inner and the outer mitochon-
drial membranes independently (Fig. 3C).
5. The post-mitochondrial phase of apoptosis:
how mitochondria kill cells
Induction of PT has dramatic consequences on
intermediate metabolism. The resulting uncoupling
of the respiratory chain leads to the cessation of
ATP synthesis. Simultaneously, mitochondria start
to hyperproduce superoxide anions which can lead
to the oxidation of mitochondrial products, such as
Fig. 3. Putative relationship between mitochondrial Bcl-2 ef-
fects, PT pore opening and cytochrome c release. (A) Bcl-2
could primarily a¡ect PT pore opening, which accounts for the
v8m collapse (once the PT pore is irreversibly opened) and cy-
tochrome c release. (B) Bcl-2 could have a primary e¡ect on
the mitochondrial membrane, thereby retaining cytochrome c in
the intermembrane space. Cytochrome c release (which inter-
rupts electron transfer on the respiratory chain) would indi-
rectly cause PT and/or dissipation of the v8m. (C) Cytochrome
c release and PT pore opening could be separate phenomena
which both are inhibited by Bcl-2.
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the inner membrane component cardiolipin. PT also
causes the depletion or oxidation of non-oxidized
glutathione and of NAD(P)2 [9,18,41,90]. A disrup-
tion of Ca2 homeostasis with an increase of cyto-
solic Ca2 levels appears to be secondary to the per-
turbed redox regulation [41]. Moreover, PT causes a
cytosolic acidi¢cation [91]. In synthesis, PT provokes
several lethal perturbations including a collapse in
bioenergetic status, redox equilibrium, and ion ho-
meostasis.
Mitochondria can liberate at least two di¡erent
factors relevant to apoptosis (Fig. 4). First, mito-
chondrial release a V50 kDa apoptosis-inducing fac-
tor (AIF). AIF su⁄ces to activate caspase-3 and to
activate endonucleases in isolated nuclei [10,14,17].
Second, mitochondria release cytochrome c (formerly
called Apaf-2), which, together with additional fac-
tors, namely Apaf-1 (the mammalian CED-4 homo-
log, which binds to the outer mitochondrial mem-
brane), ATP, and a probably cytosolic 45 kDa
protein (Apaf-3), can proteolytically activate casp-
ase-3, which, in turn, cleaves and activates DNA
fragmentation factor (DFF), an endonuclease activa-
tor acting on the nucleus [25,89,92]. Cytochrome c
intervenes in this system in its holo-form (that is with
the heme group attached), although its structure
rather than its electron acceptor function appears
to be essential for is pro-apoptotic function [29].
The relationship between these two systems (AIF
vs. Apaf-1/2/3) of caspase and endonuclease activa-
tion is unclear. However, it appears that AIF does
not require cytochrome c to exert is apoptogenic ac-
tivity. Addition of cytochrome c to AIF does not
augment its activity, and AIF devoid of contaminat-
ing cytochrome c is still active (unpublished). The
Apaf-1/2/3-mediated activation of caspase-3 and
DFF is inhibited by Ac-DEVD.cmk [25,92], whereas
AIF-mediated e¡ects on nuclei and caspase-3 are re-
sistant to Ac-DEVD.cmk and are inhibited by Z-
VAD.fmk [10,14,17]. This suggests that both systems
can operate independently of each other. The molec-
ular cloning of Apaf-3 and AIF should furnish a ¢rm
response on the relative biological importance of
these apoptogenic factors.
Triggering of PT can cause both necrosis and
apoptosis (for review see [4,6]. If PT is involved in
both apoptosis and necrosis, what determines the
di¡erence between both modes of cell death? Appar-
ently, the activation of apoptogenic proteases is cru-
cial of this di¡erence. N-Benzyloxycarbonyl-Val-Ala-
Asp-£uoromethylketone (Z-VAD.fmk) is a direct in-
hibitor of several ICE-like caspases and AIF. Z-
VAD.fmk also suppresses all major signs of nuclear
apoptosis which normally become apparent upon
pharmacological induction of PT [10,15,18] or after
hyperexpression of bax [26]. In strict contrast to its
e⁄cient inhibitory e¡ect on nuclear apoptosis, how-
ever, Z-VAD.fmk fails to prevent cytolysis [18,26,93].
Rather than preventing cell death as such, it thus
induces a shift from the apoptotic to the necrotic
mode of cell death. Another determining factor for
the ‘decision’ between apoptosis and necrosis is the
intracellular ATP content. Manipulations tending to
reduce cellular ATP levels favor the necrotic over the
Fig. 4. Caspase and nuclease activation after release of soluble
proteins from mitochondria. Several di¡erent factors are re-
leased from mitochondria during apoptosis: AIF (which is asso-
ciated with the intermembrane space), cytochrome c (in the in-
termembrane space) and Apaf-1 (associated with the
mitochondrial surface, probably with Bcl-2). Whereas AIF su⁄-
ces to proteolytically activate caspase-3 and nuclear endonu-
cleases, cytochrome c has to interact with additional proteins in
the so-called ‘apoptosome’. The apoptosome implies the partici-
pation of cytochrome c, Apaf-1 (which binds ATP) and Apaf-3
(caspase-9), which together activate pro-caspase-3. Caspase-3
cleaves and activates DNA fragmentation factor (DFF), which
then activates endonucleases.
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apoptotic mode of cell death, whereas an increased
ATP supply (provided by glycolytic substrates) has
the opposite e¡ect [94,95].
The notion that PT can trigger both apoptosis
(when Z-VAD.fmk-inhibitable proteases come into
action) and necrosis (when such proteases fail to
act) is compatible with the ¢nding that many drugs
induce necrosis at high doses and apoptosis at lower
(‘subnecrotic’) doses. When PT is induced in a mas-
sive, rapid fashion heavily compromising cellular me-
tabolism, necrosis occurs before apoptogenic pro-
teases come into action. In contrast, induction of
PT in a more smooth, protracted fashion, allows
for the activation and action of proteases before
ATP depletion causes cell death. Thus, the intensity
of the PT-inducing stimulus may determine which
among the two major consequences of PT wins the
race: (1) a bioenergetic catastrophe culminating in
necrosis; or (2) the activation/action of apoptogenic
proteases. It appears plausible that the availability of
pre-formed apoptogenic proteases (and their endog-
enous inhibitors?), as well as their post-translational
modi¢cation (e.g. inactivation by oxidation or nitro-
sylation), could in£uence the propensity of cells to
die from apoptosis versus necrosis. The relative
apoptosis/necrosis susceptibility might also be in£u-
enced by the ratio between glycolytic and respiratory
ATP generation, which would be di¡erentially af-
fected by the disruption of mitochondrial function.
6. Concluding remarks and perspectives
The involvement of mitochondria in apoptosis has
several important consequences. First, it provides a
theory for the evolutionary origin of apoptosis
(which predates the metazoon radiation). According
to this theory, apoptosis could have arisen as a by-
product of endosymbiosis [3]. Second, it provides a
new method for the determination of apoptosis, the
assessment of v8m, with the advantage of measuring
an early event that can occur in situ before cells are
removed by heterophagy [35]. Third, it has major
implications for our understanding of apoptosis reg-
ulation, both in physiology and pathology. It is
tempting to establish links between mitochondrial
or nuclear mutations a¡ecting mitochondrial func-
tion and an increased apoptotic decay leading to de-
generative diseases. Similarly, it may be speculated
that changes in the metabolic function induced by
Bcl-2 and its homologs may explain speci¢c metabol-
ic features of tumor cells. Fourth, the implication of
mitochondria in apoptosis weakens the paradigmatic
antinomy between necrosis and apoptosis. Appar-
ently, mitochondria are involved in both modes of
cell death and that the intensity of the mitochondrial
membrane disruption as well as non-mitochondrial
factors (availability of ATP, caspases etc.) determine
whether cells lyse before caspases and endonucleases
are activated (which results in necrosis) or after the
activation of these enzymes (which causes apoptosis).
Fifth, it provides important clues for the develop-
ment of cytotoxic or cytoprotective drugs. Cytopro-
tective drugs must act at the pre-mitochondrial or
mitochondrial stage of apoptosis. Compounds that
only interfere with post-mitochondrial e¡ects are
likely to be ine⁄cient. On the contrary, cytotoxic
agents a¡ecting the megachannel might facilitate
the induction of cell death and overcome apoptosis
resistance in cancer cells.
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